AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
.jpg)
Highlights
- Decades of research has shown Psychedelic substance such as LSD and Psilocybin can treat the mental disorder more efficiently than conventional therapies.
- The market size of the Psychedelic treatment was at USD five billion in 2020 and is expected to grow further.
- Some companies have tasted successes and debuted on the US stock exchange through IPO
Psychedelics such as LSD and Psilocybin has been known for the treatment of mental disorder like depression, anxiety, PTSD. Decades of research has demonstrated and shown promising results that some psychedelics substance presents to treat mental health issues, better than the conventional therapies.
According to the market experts, the Psychedelic treatments market size was estimated to be over USD 4 billion in 2020. Hence, multiple companies are rushing to start operations in the sector and gain market share.
Some companies have tasted successes and debuted on the US stock exchange through the IPO route. At present, London Stock Exchange doesn’t have companies listed from the Psychedelics segment, but still some UK-based companies have significant operations in the UK markets and other countries.
Let us look at UK-based companies that have business operations in the psychedelic market and could be probable of London listing:
Small Pharma
This neuropharmaceutical company is based in London. The company focus on identifying innovative treatment for the depression and other mental health disorders. The company has collaborated with experts from the Imperial College, London, for the phase-1 clinical trial of DMT-assisted therapy, which provides potential transformative healing. Clinical trials are going on since February 2021 for the patients as well as healthy individuals in London.
The clinical trial will be conducted in two parts. The Part A will test the tolerance and safety of DMT therapy in healthy volunteers, while the Part B will test the efficiency of DMT therapy on the patient with moderate depressive disorders.
Compass Pathways
The UK-based company focuses on the research of psilocybin therapy to treat mental disorders. The company works on Psilocybin which is the active substance found in mushrooms. The company has developed synthesised formulation, COMP 360 and is doing research on the effectiveness of the therapy. The company has received US-FDA approval for the therapy, and its stock is listed on the NASDAQ under the ticker name CMPS.
Clarify Pharma
London-based company focus on the investment in the bioscience and life science company. The company’s team has proven experience in scaling the business within the psychedelic medical sector. The company has a keen interest in advance evidence-based psychedelic medicine to help patients tackle the mental health issue. The company has been focusing on a portfolio of leading clinical psychedelics companies.
Related Article: Is Psychedelic Treatment MDMA A Cure for PTSD?
LocoSoco Group Plc
The company operates in the technology segment, listed on the Direct Market segment of Vienna MTF. It has announced a new distribution agreement with Silo Wellness Inc., a leading psychedelics company listed on the Canadian Securities Exchange. According to the agreement, LocoSoco Group plc will be the exclusive UK-based market distributor for Silo Wellness’s Marley One branded mushroom products. The exclusive agreement is based on the minimum order commitment of USD 1.4 million by LocoSoco for the Marley One products.
